View Older Stories View More Recent Stories

May 1, 2018 04:15PM TESARO Announces Participation in Two Investor Conferences
May 1, 2018 04:15PM TESARO Announces Participation in Two Investor Conferences
Apr 19, 2018 04:15PM TESARO to Announce First-Quarter 2018 Financial Results on May 3, 2018
Apr 19, 2018 04:15PM TESARO to Announce First-Quarter 2018 Financial Results on May 3, 2018
Apr 16, 2018 09:01AM TESARO (TSRO) Reports Summarized Initial Data from Phase 1 GARNET trial of TSR-042 (anti-PD-1 antibody)
Apr 16, 2018 09:00AM TESARO Summarizes TSR-042 Clinical Data Presented at AACR
Apr 16, 2018 09:00AM TESARO Summarizes TSR-042 Clinical Data Presented at AACR
Apr 11, 2018 08:31AM TESARO (TSRO) Announces Exclusive Distribution Agreement with Medison Pharma to Commercialize ZEJULA in Israel
Apr 11, 2018 08:30AM TESARO and Medison Enter Into Exclusive Distribution Agreement to Commercialize ZEJULA® in Israel
Apr 11, 2018 08:30AM TESARO and Medison Enter Into Exclusive Distribution Agreement to Commercialize ZEJULA® in Israel
Apr 11, 2018 08:30AM TESARO and Medison Enter Into Exclusive Distribution Agreement to Commercialize ZEJULA® in Israel
Mar 14, 2018 04:50PM TESARO Announces Data Presentations at the 2018 American Association for Cancer Research Annual Meeting
Mar 14, 2018 04:50PM TESARO Announces Data Presentations at the 2018 American Association for Cancer Research Annual Meeting
Mar 1, 2018 04:15PM TESARO Announces Participation at Two Investor Conferences
Mar 1, 2018 04:15PM TESARO Announces Participation at Two Investor Conferences
Feb 27, 2018 04:05PM TESARO Announces Fourth-Quarter and Full-Year 2017 Operating Results
Feb 27, 2018 04:05PM TESARO Announces Fourth-Quarter and Full-Year 2017 Operating Results
Feb 26, 2018 03:00PM TESARO (TSRO) Announces Collaboration to Evaluate Combination of ZEJULA and Anti-PD-L1 Cancer Immunotherapy in Metastatic Bladder Cancer
Feb 26, 2018 03:00PM TESARO Announces Collaboration to Evaluate Combination of ZEJULA® (Niraparib) and Anti-PD-L1 Cancer Immunotherapy in Metastatic Bladder Cancer
Feb 26, 2018 03:00PM TESARO Announces Collaboration to Evaluate Combination of ZEJULA® (Niraparib) and Anti-PD-L1 Cancer Immunotherapy in Metastatic Bladder Cancer
Feb 2, 2018 09:48AM TESARO to Announce Fourth-Quarter 2017 Financial Results on February 27, 2018
Feb 2, 2018 09:48AM TESARO to Announce Fourth-Quarter 2017 Financial Results on February 27, 2018
Jan 16, 2018 06:39AM TESARO (TSRO) Reports Increased Label Precautions to U.S. Prescribing Information for VARUBI (rolapitant) Injectable Emulsion
Jan 12, 2018 05:30PM TESARO Announces Updates to the U.S. Prescribing Information for VARUBI® (rolapitant) Injectable Emulsion
Jan 12, 2018 05:30PM TESARO Announces Updates to the U.S. Prescribing Information for VARUBI® (rolapitant) Injectable Emulsion
Dec 15, 2017 05:46AM TESARO (TSRO) Reports Availability of ZEJULA (niraparib) for Women With Recurrent Ovarian Cancer in Germany
Dec 15, 2017 04:00AM TESARO Announces Availability of ZEJULA® (niraparib) for Women With Recurrent Ovarian Cancer in Germany
Dec 15, 2017 04:00AM TESARO Announces Availability of ZEJULA® (niraparib) for Women With Recurrent Ovarian Cancer in Germany
Nov 28, 2017 08:07AM TESARO (TSRO) VARUBI Launches in U.S.
Nov 28, 2017 08:00AM TESARO Announces Availability of VARUBI® (rolapitant) IV for Delayed Nausea and Vomiting Associated With Cancer Chemotherapy in the United States
Nov 22, 2017 04:05PM TESARO Announces Participation in Two Investor Conferences
Nov 21, 2017 08:00AM TESARO Secures $500 Million Non-Dilutive Term Loan Financing
Nov 20, 2017 08:00AM TESARO’s Mary Lynne Hedley and Lonnie Moulder Named EY National Entrepreneurs of the Year®
Nov 20, 2017 07:02AM TESARO (TSRO) Announce EC Approval of ZEJULA to Treat Ovarian Cancer
Nov 20, 2017 07:00AM TESARO Announces European Commission Approval of ZEJULA® for Women With Recurrent Ovarian Cancer
Nov 7, 2017 04:05PM TESARO Announces Third-Quarter 2017 Operating Results
Oct 26, 2017 05:47AM TESARO (TSRO) Announces FDA Approval of VARUBI for Delayed Nausea and Vomiting Associated Chemo
Oct 25, 2017 07:15PM TESARO Announces U.S. FDA Approval of VARUBI® IV for Delayed Nausea and Vomiting Associated With Cancer Chemotherapy
Oct 24, 2017 04:15PM TESARO to Announce Third-Quarter 2017 Financial Results on November 7, 2017
Oct 23, 2017 04:15PM TESARO Announces Participation at Two Investor Conferences
Oct 18, 2017 08:00AM The Foundation for Women’s Cancer and TESARO Announce 2nd Year of Partnership Supporting the National Race to End Women’s Cancer
Sep 28, 2017 04:30PM TESARO Expands Our Way Forward Program for the Ovarian Cancer Community and Partners With Olympic Gymnast Shannon Miller
Sep 15, 2017 07:46AM TESARO (TSRO) Announces Positive CHMP Opinion for ZEJULA
Sep 15, 2017 07:45AM TESARO Receives Positive CHMP Opinion for ZEJULA®
Sep 11, 2017 08:02AM TESARO (TSRO) Summarizes ZEJULA and TSR-042 Data Presented at ESMO
Sep 11, 2017 08:00AM TESARO Summarizes ZEJULA and TSR-042 Data Presented at the 2017 ESMO Annual Meeting
Aug 25, 2017 08:01AM TESARO Announces Nine Data Presentations at the 2017 European Society for Medical Oncology (ESMO) Annual Meeting
Aug 23, 2017 04:15PM TESARO Announces Participation at Four Investor Conferences
Aug 8, 2017 04:05PM TESARO Announces Second-Quarter 2017 Operating Results
Jul 27, 2017 07:19AM TESARO (TSRO), Takeda Enter Pact for Niraparib in Japan
View More Recent Stories View Older Stories